PT-004 - PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF PRIMARY CLINICAL OUTCOMES IN TREATING DRUG-SENSITIVE TUBERCULOSIS WITH FOUR-MONTH HIGH-DOSE RIFAPENTINE WITH AND WITHOUT MOXIFLOXACIN (STUDY 31/A5349).

V. Chang¹, M. Imperial¹, W. Whitworth², W. Carr², E. Kurbatova², A. Vernon², M. Weiner³, K. Dooley⁴, S. Dorman⁵, P. Nahid¹, P. Phillips¹, S. Swindells⁶, R. Chaisson⁴, J. Johnson⁷, N. Viet Nhung², R. Savic¹; ¹University of California San Francisco, San Francisco, CA, USA, ²Centers for Disease Control and Prevention, Atlanta, GA, USA, ³University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, ⁴Johns Hopkins Medicine, Baltimore, MD, USA, ⁵Medical University of South Carolina, Charleston, SC, USA, ⁶University of Nebraska, Omaha, NE, USA, ⁷Case Western Reserve University, Cleveland, OH, USA.